Companies Dominating the Androgen Treatment Landscape
- F. Hoffmann La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Bayer AG
- GlaxoSmithKline plc.
- Sanofi S.A.
- Amgen Inc.
- Merck & Co. Inc.
- AbbiVie Inc.
- Eli Lilly and Company
- Bausch Health
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of angiosarcoma treatment is assessed at USD 292.76 million.
The angiosarcoma treatment market size was valued at USD 279.68 million in 2024 and is expected to reach USD 560.97 million by 2037, expanding at around 5.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of cancer and growing technological advancement will boost the market growth.
North America industry is poised to dominate majority revenue share of 35% by 2037, driven by development of new medical infrastructure in the region.
The major players in the market are Bayer AG, GlaxoSmithKline plc., Sanofi S.A., Amgen Inc., Merck & Co. Inc., AbbiVie Inc., Eli Lilly and Company, Bausch Health, and others.
